{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:12:42Z","timestamp":1780445562949,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,26]]},"DOI":"10.7759\/cureus.91004","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T07:36:05Z","timestamp":1756193765000},"source":"Crossref","is-referenced-by-count":1,"title":["Quality of Life and Treatment Satisfaction in Patients Receiving Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion: A Cross-Sectional Study"],"prefix":"10.7759","author":[{"given":"Konstantinos","family":"Flindris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysa","family":"Chatzipetrou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Papafotiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Kaliardas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Koumpoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Melissourgos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15201","article-title":"The management of neovascular age-related macular degeneration: a systematic literature review of patient-reported outcomes, patient mental health and caregiver burden","volume":"101","author":"Gale RP","year":"2023","unstructured":"Gale RP, Finger RP, Eldem B, et al.. The management of neovascular age-related macular degeneration: a systematic literature review of patient-reported outcomes, patient mental health and caregiver burden. Acta Ophthalmol. 2023, 101:e26-42. 10.1111\/aos.15201","journal-title":"Acta Ophthalmol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2021.02.009","article-title":"Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy","volume":"9","author":"Deng Y","year":"2022","unstructured":"Deng Y, Qiao L, Du M, Qu C, Wan L, Li J, Huang L. Age-related macular degeneration: epidemiology, genetics, pathophysiology, diagnosis, and targeted therapy. Genes Dis. 2022, 9:62-79. 10.1016\/j.gendis.2021.02.009","journal-title":"Genes Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000657","article-title":"Age-related macular degeneration therapy: a review","volume":"31","author":"Ammar MJ","year":"2020","unstructured":"Ammar MJ, Hsu J, Chiang A, Ho AC, Regillo CD. Age-related macular degeneration therapy: a review. Curr Opin Ophthalmol. 2020, 31:215-21. 10.1097\/ICU.0000000000000657","journal-title":"Curr Opin Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S143508","article-title":"Recent developments in age-related macular degeneration: a review","volume":"12","author":"Al-Zamil WM","year":"2017","unstructured":"Al-Zamil WM, Yassin SA. Recent developments in age-related macular degeneration: a review. Clin Interv Aging. 2017, 12:1313-30. 10.2147\/CIA.S143508","journal-title":"Clin Interv Aging"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-016-3384-0","article-title":"Psychological impact of anti-VEGF treatments for wet macular degeneration-a review","volume":"254","author":"Senra H","year":"2016","unstructured":"Senra H, Ali Z, Balaskas K, Aslam T. Psychological impact of anti-VEGF treatments for wet macular degeneration-a review. Graefes Arch Clin Exp Ophthalmol. 2016, 254:1873-80. 10.1007\/s00417-016-3384-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddx228","article-title":"Genetics of age-related macular degeneration (AMD)","volume":"26","author":"DeAngelis MM","year":"2017","unstructured":"DeAngelis MM, Owen LA, Morrison MA, et al.. Genetics of age-related macular degeneration (AMD). Hum Mol Genet. 2017, 26:R45-50. 10.1093\/hmg\/ddx228","journal-title":"Hum Mol Genet"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27165089","article-title":"Recent advances in age-related macular degeneration therapies","volume":"27","author":"Fabre M","year":"2022","unstructured":"Fabre M, Mateo L, Lamaa D, et al.. Recent advances in age-related macular degeneration therapies. Molecules. 2022, 27:10.3390\/molecules27165089","journal-title":"Molecules"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S214098","article-title":"Burden of treatment among patients undergoing intravitreal injections for diabetic macular oedema in Australia","volume":"12","author":"Spooner KL","year":"2019","unstructured":"Spooner KL, Guinan G, Koller S, Hong T, Chang AA. Burden of treatment among patients undergoing intravitreal injections for diabetic macular oedema in Australia. Diabetes Metab Syndr Obes. 2019, 12:1913-21. 10.2147\/DMSO.S214098","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-020-04798-2","article-title":"Systematic review: non-adherence and non-persistence in intravitreal treatment","volume":"258","author":"Ehlken C","year":"2020","unstructured":"Ehlken C, Ziemssen F, Eter N, Lanzl I, Kaymak H, Lommatzsch A, Schuster AK. Systematic review: non-adherence and non-persistence in intravitreal treatment. Graefes Arch Clin Exp Ophthalmol. 2020, 258:2077-90. 10.1007\/s00417-020-04798-2","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-022-00631-7","article-title":"The patient voice in neovascular age-related macular degeneration: findings from a qualitative study","volume":"12","author":"Talks SJ","year":"2023","unstructured":"Talks SJ, Daien V, Mitchell P, et al.. The patient voice in neovascular age-related macular degeneration: findings from a qualitative study. Ophthalmol Ther. 2023, 12:561-75. 10.1007\/s40123-022-00631-7","journal-title":"Ophthalmol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-8-4","article-title":"Psychometric properties of the Greek version of the NEI-VFQ 25","volume":"8","author":"Labiris G","year":"2008","unstructured":"Labiris G, Katsanos A, Fanariotis M, Tsirouki T, Pefkianaki M, Chatzoulis D, Tsironi E. Psychometric properties of the Greek version of the NEI-VFQ 25. BMC Ophthalmol. 2008, 8:4. 10.1186\/1471-2415-8-4","journal-title":"BMC Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-017-0492-8","article-title":"Treatment satisfaction of patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents","volume":"38","author":"Marakis TP","year":"2018","unstructured":"Marakis TP, Koutsandrea C, Chatzistefanou KI, Tountas Y. Treatment satisfaction of patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor agents. Int Ophthalmol. 2018, 38:565-76. 10.1007\/s10792-017-0492-8","journal-title":"Int Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract11030081","article-title":"The effect of ranibizumab loading treatment on vision-related quality of life in diabetic macular edema","volume":"11","author":"Daldal H","year":"2021","unstructured":"Daldal H, Turkyilmaz M, Balikoglu Yilmaz M, Berberoglu U. The effect of ranibizumab loading treatment on vision-related quality of life in diabetic macular edema. Clin Pract. 2021, 11:659-70. 10.3390\/clinpract11030081","journal-title":"Clin Pract"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.03.012","article-title":"Vision-related quality of life in patients with diabetic macular edema treated with intravitreal aflibercept: the AQUA study","volume":"3","author":"Garweg JG","year":"2019","unstructured":"Garweg JG, Stefanickova J, Hoyng C, Schmelter T, Niesen T, Sowade O, Sivaprasad S. Vision-related quality of life in patients with diabetic macular edema treated with intravitreal aflibercept: the AQUA study. Ophthalmol Retina. 2019, 3:567-75. 10.1016\/j.oret.2019.03.012","journal-title":"Ophthalmol Retina"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12955-016-0536-1","article-title":"Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study","volume":"14","author":"Bertelmann T","year":"2016","unstructured":"Bertelmann T, Feltgen N, Scheffler M, Hufenbach U, Wiedon A, Wilhelm H, Ziemssen F. Vision-related quality of life in patients receiving intravitreal ranibizumab injections in routine clinical practice: baseline data from the German OCEAN study. Health Qual Life Outcomes. 2016, 14:132. 10.1186\/s12955-016-0536-1","journal-title":"Health Qual Life Outcomes"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17587-0","article-title":"Time course of changes in vision-related quality of life following intravitreal ranibizumab treatment for branch retinal vein occlusion","volume":"12","author":"Morikawa S","year":"2022","unstructured":"Morikawa S, Okamoto F, Murakami T, Sugiura Y, Hiraoka T, Okamoto Y, Oshika T. Time course of changes in vision-related quality of life following intravitreal ranibizumab treatment for branch retinal vein occlusion. Sci Rep. 2022, 12:13428. 10.1038\/s41598-022-17587-0","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.49890","article-title":"The role of inflammation in age-related macular degeneration","volume":"16","author":"Tan W","year":"2020","unstructured":"Tan W, Zou J, Yoshida S, Jiang B, Zhou Y. The role of inflammation in age-related macular degeneration. Int J Biol Sci. 2020, 16:2989-3001. 10.7150\/ijbs.49890","journal-title":"Int J Biol Sci"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-020-01561-3","article-title":"Predictors of health-related quality of life in Chinese patients receiving treatment for neovascular age-related macular degeneration: a prospective longitudinal study","volume":"20","author":"Bian W","year":"2020","unstructured":"Bian W, Wan J, Tan M, Su J, Yuan Y, Wang Z, Li S. Predictors of health-related quality of life in Chinese patients receiving treatment for neovascular age-related macular degeneration: a prospective longitudinal study. BMC Ophthalmol. 2020, 20:291. 10.1186\/s12886-020-01561-3","journal-title":"BMC Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/opo.12984","article-title":"Predictors of vision-related quality of life in patients with macular oedema receiving intra-vitreal anti-VEGF treatment","volume":"42","author":"Rausch-Koster PT","year":"2022","unstructured":"Rausch-Koster PT, Rennert KN, Heymans MW, Verbraak FD, van Rens GH, van Nispen RM. Predictors of vision-related quality of life in patients with macular oedema receiving intra-vitreal anti-VEGF treatment. Ophthalmic Physiol Opt. 2022, 42:849-57. 10.1111\/opo.12984","journal-title":"Ophthalmic Physiol Opt"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.1660","article-title":"Defining nonadherence and nonpersistence to anti-vascular endothelial growth factor therapies in neovascular age-related macular degeneration","volume":"139","author":"Okada M","year":"2021","unstructured":"Okada M, Wong TY, Mitchell P, et al.. Defining nonadherence and nonpersistence to anti-vascular endothelial growth factor therapies in neovascular age-related macular degeneration. JAMA Ophthalmol. 2021, 139:769-76. 10.1001\/jamaophthalmol.2021.1660","journal-title":"JAMA Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S40215","article-title":"Aflibercept in wet AMD: specific role and optimal use","volume":"7","author":"Semeraro F","year":"2013","unstructured":"Semeraro F, Morescalchi F, Duse S, Parmeggiani F, Gambicorti E, Costagliola C. Aflibercept in wet AMD: specific role and optimal use. Drug Des Devel Ther. 2013, 7:711-22. 10.2147\/DDDT.S40215","journal-title":"Drug Des Devel Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20042879","article-title":"Life quality in patients with impaired visual acuity undergoing intravitreal medication applications","volume":"20","author":"Kola\u010dko \u0160","year":"2023","unstructured":"Kola\u010dko \u0160, Predovi\u0107 J, Tomi\u0107 A, Or\u0161uli\u0107 V. Life quality in patients with impaired visual acuity undergoing intravitreal medication applications. Int J Environ Res Public Health. 2023, 20:10.3390\/ijerph20042879","journal-title":"Int J Environ Res Public Health"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1159\/000433448","article-title":"Quality of life in patients suffering from active exudative age-related macular degeneration: the EQUADE study","volume":"234","author":"Matamoros E","year":"2015","unstructured":"Matamoros E, Maurel F, L\u00e9on N, et al.. Quality of life in patients suffering from active exudative age-related macular degeneration: the EQUADE study. Ophthalmologica. 2015, 234:151-9. 10.1159\/000433448","journal-title":"Ophthalmologica"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1177\/11206721211003488","article-title":"Intravitreal injections during COVID-19 outbreak: Protective measures, total duration of care and perceived quality of care in a tertiary retina center","volume":"32","author":"Denys P","year":"2022","unstructured":"Denys P, Miere A, Colantuono D, Jung C, Souied EH. Intravitreal injections during COVID-19 outbreak: Protective measures, total duration of care and perceived quality of care in a tertiary retina center. Eur J Ophthalmol. 2022, 32:372-6. 10.1177\/11206721211003488","journal-title":"Eur J Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-023-02261-x","article-title":"Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis","volume":"12","author":"Shahzad H","year":"2023","unstructured":"Shahzad H, Mahmood S, McGee S, et al.. Non-adherence and non-persistence to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy: a systematic review and meta-analysis. Syst Rev. 2023, 12:92. 10.1186\/s13643-023-02261-x","journal-title":"Syst Rev"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1159\/000538975","article-title":"Patient experience survey of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration and diabetic macular edema","volume":"67","author":"Holekamp N","year":"2024","unstructured":"Holekamp N, Gentile B, Giocanti-Aur\u00e9gan A, et al.. Patient experience survey of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration and diabetic macular edema. Ophthalmic Res. 2024, 67:311-21. 10.1159\/000538975","journal-title":"Ophthalmic Res"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-077175","article-title":"Patient perspectives and barriers in the treatment of neovascular age-related macular degeneration in Denmark: a qualitative study","volume":"13","author":"Thinggaard BS","year":"2023","unstructured":"Thinggaard BS, Pedersen M, Sorensen TL, Grauslund J, Stokholm L. Patient perspectives and barriers in the treatment of neovascular age-related macular degeneration in Denmark: a qualitative study. BMJ Open. 2023, 13:e077175. 10.1136\/bmjopen-2023-077175","journal-title":"BMJ Open"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.1091","article-title":"Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial","volume":"140","author":"Chang MA","year":"2022","unstructured":"Chang MA, Kapre A, Kaufman D, et al.. Patient preference and treatment satisfaction with a port delivery system for ranibizumab vs intravitreal injections in patients with neovascular age-related macular degeneration: a randomized clinical trial. JAMA Ophthalmol. 2022, 140:771-8. 10.1001\/jamaophthalmol.2022.1091","journal-title":"JAMA Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/402416-quality-of-life-and-treatment-satisfaction-in-patients-receiving-intravitreal-injection-therapy-for-neovascular-age-related-macular-degeneration-diabetic-macular-edema-and-retinal-vein-occlusion-a-cross-sectional-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T07:36:06Z","timestamp":1756193766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/402416-quality-of-life-and-treatment-satisfaction-in-patients-receiving-intravitreal-injection-therapy-for-neovascular-age-related-macular-degeneration-diabetic-macular-edema-and-retinal-vein-occlusion-a-cross-sectional-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.91004","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,26]]}}}